Search Results - "HEBART, H"

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants by Hehlmann, R, Lauseker, M, Saußele, S, Pfirrmann, M, Krause, S, Kolb, H J, Neubauer, A, Hossfeld, D K, Nerl, C, Gratwohl, A, Baerlocher, G M, Heim, D, Brümmendorf, T H, Fabarius, A, Haferlach, C, Schlegelberger, B, Müller, M C, Jeromin, S, Proetel, U, Kohlbrenner, K, Voskanyan, A, Rinaldetti, S, Seifarth, W, Spieß, B, Balleisen, L, Goebeler, M C, Hänel, M, Ho, A, Dengler, J, Falge, C, Kanz, L, Kremers, S, Burchert, A, Kneba, M, Stegelmann, F, Köhne, C A, Lindemann, H W, Waller, C F, Pfreundschuh, M, Spiekermann, K, Berdel, W E, Müller, L, Edinger, M, Mayer, J, Beelen, D W, Bentz, M, Link, H, Hertenstein, B, Fuchs, R, Wernli, M, Schlegel, F, Schlag, R, de Wit, M, Trümper, L, Hebart, H, Hahn, M, Thomalla, J, Scheid, C, Schafhausen, P, Verbeek, W, Eckart, M J, Gassmann, W, Pezzutto, A, Schenk, M, Brossart, P, Geer, T, Bildat, S, Schäfer, E, Hochhaus, A, Hasford, J

“…Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day ( n =400) could be optimized by doubling the…”
Get full text

SAFETY AND EFFECTIVENESS IN R/R CLL PATIENTS TREATED WITH VENETOCLAX IN COMBINATION WITH RITUXIMAB UNDER REAL‐WORLD CONDITIONS IN AUSTRIA, GERMANY, AND SWITZERLAND by Schwaner, I., Hebart, H., Losem, C., Wolff, T., Schmidt, B., Rossi, D., Lehmann, C., Benzel, J., Huelsenbeck, J., Pichler, P.

Get full text

Diagnosis of invasive fungal infections in hematology and oncology—guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO) by Ruhnke, M., Böhme, A., Buchheidt, D., Cornely, O., Donhuijsen, K., Einsele, H., Enzensberger, R., Hebart, H., Heussel, C.P., Horger, M., Hof, H., Karthaus, M., Krüger, W., Maschmeyer, G., Penack, O., Ritter, J., Schwartz, S.

“…Invasive fungal infections (IFIs) are a primary cause of morbidity and mortality in patients with hematological malignancies. Establishing a definite diagnosis…”
Get full text

SAFETY AND EFFECTIVENESS OF VENETOCLAX MONOTHERAPY IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY CLL UNDER REAL‐LIFE CONDITIONS – DATA FROM THE OBSERVATIONAL STUDY VERVE by Schwaner, I., Hebart, H., Losem, C., Wolff, T., Huelsenbeck, J., Schmidt, B., Rossi, D., Noesslinger, T.

Get full text

Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis by Schlenk, R F, Stegelmann, F, Reiter, A, Jost, E, Gattermann, N, Hebart, H, Waller, C, Hochhaus, A, Platzbecker, U, Schafhausen, P, Blau, I W, Verbeek, W, Heidel, F H, Werner, M, Kreipe, H, Teleanu, V, Benner, A, Döhner, H, Grießhammer, M, Döhner, K

“…Myeloproliferative neoplasm (MPN)-associated myelofibrosis is a MPN characterized by bone marrow fibrosis, cytopenias, splenomegaly and constitutional…”
Get full text

A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin Bin patients after allo-SCT by Hebart, H, Klingspor, L, Klingebiel, T, Loeffler, J, Tollemar, J, Ljungman, P, Wandt, H, Schaefer-Eckart, K, Dornbusch, HJ, Meisner, C

Get full text

TRICC-C: Nintedanib vs. placebo in patients receiving mFOLFOX6 for metastatic, chemorefractory colorectal cancer: Final results from the randomized phase II trial of the AIO by Ettrich, T J, Berger, A W, Decker, T, Hofheinz, R D, Heinemann, V, Hoffmann, T, Hebart, H F, Herrmann, T, Hannig, C-V, Büchner-Steudel, P, Bartholomäus, H, Güthle, M, Perkhofer, L, Seufferlein, T

Get full text

P647: SAFETY AND EFFECTIVENESS OF VENETOCLAX MONOTHERAPY IN R/R CLL PATIENTS WITH OR WITHOUT RISK‐ASSOCIATED GENETIC MARKERS – DATA FROM THE OBSERVATIONAL VERVE STUDY by Schwaner, I., Hebart, H., Losem, C., Wolff, T., Famulla, K., Huelsenbeck, J., Schmidt, B., Nösslinger, T., Rossi, D.

Get full text

P646: EFFECTIVENESS AND SAFETY OF VENETOCLAX IN COMBINATION WITH RITUXIMAB (VENR) IN R/R CLL PATIENTS WITH OR WITHOUT RISK‐ASSOCIATED GENETIC MARKERS – DATA FROM THE OBSERVATIONAL VERVE STUDY by Schwaner, I., Hebart, H., Losem, C., Wolff, T., Famulla, K., Huelsenbeck, J., Schmidt, B., Nösslinger, T., Rossi, D.

Get full text

A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT by Hebart, H, Klingspor, L, Klingebiel, T, Loeffler, J, Tollemar, J, Ljungman, P, Wandt, H, Schaefer-Eckart, K, Dornbusch, H J, Meisner, C, Engel, C, Stenger, N, Mayer, T, Ringden, O, Einsele, H

“…We compared the efficacy and safety of empirical plus PCR-based vs empirical liposomal amphotericin B treatment after Allo-SCT. Allo-SCT recipients were…”
Get full text

Drug monitoring detects under- and overdosing in patients receiving 5-fluorouracil-containing chemotherapy—results of a prospective, multicenter German observational study by Li, M., Mindt, S., Lück, A., Hutzschenreuter, U., Kollendt, M., Lathan, B., Zöller, T., Frank-Gleich, S., Lorentz, C., Lamberti, C., Sick, C., Zingerle, M., Tesch, H., Stein, W., Hebart, H., Stosiek, C., Sandner, R., Fries, S., Burkholder, I., Hofheinz, R.-D.

“…Body surface area (BSA)-based dosing of 5-fluorouracil (5-FU) results in marked inter-individual variability in drug levels, whereas determination of plasma…”
Get full text

Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO) by Sandherr, M., Einsele, H., Hebart, H., Kahl, C., Kern, W., Kiehl, M., Massenkeil, G., Penack, O., Schiel, X., Schuettrumpf, S., Ullmann, A.J., Cornely, O.A.

“…Morbidity and mortality in patients with malignancies are increased by viral infections. These mostly are reactivations of asymptomatic latent infections. They…”
Get full text

Monocyte-derived dendritic cells are permissive to the complete replicative cycle of human cytomegalovirus by Riegler, S, Hebart, H, Einsele, H, Brossart, P, Jahn, G, Sinzger, C

“…Department of Medical Virology, University of Tübingen, Calwerstrasse 7/6, D-72076 Tübingen, Germany 1 Department of Medicine, University of Tübingen,…”
Get full text

2049 AIO-KRK-0109: A randomized phase II trial of panitumumab plus FOLFOXIRI or FOLFOXIRI alone as 1st-line treatment in RAS-wild-type metastatic colorectal cancer (mCRC) by Martens, U.M, Wessendorf, S, Knorrenschild, J. Riera, Buechner-Steudel, P, Florschuetz, A, Atzpodien, J, Greeve, J, Kanzler, S, Ettrich, T, Lindig, U, Egger, M, Hebart, H, Geissler, M

Get full text

P1055: CLINICAL AND GENETIC RESULTS OF THE PHASE IB/II TRIAL MPNSG‐0212: RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA by Stegelmann, F., Jahn, E., Koschmieder, S., Heidel, F., Hochhaus, A., Hebart, H., Isfort, S., Reiter, A., Bangerter, M., Waller, C. F., Wolleschak, D., Scheid, C., Göthert, J., Schafhausen, P., Kindler, T., Radsak, M. P., Gattermann, N., Möhle, R., Bubnoff, N., Schrade, A., Brümmendorf, T., Döhner, H., Griesshammer, M., Döhner, K.

Get full text

Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation by Einsele, H, Ehninger, G, Hebart, H, Wittkowski, KM, Schuler, U, Jahn, G, Mackes, P, Herter, M, Klingebiel, T, Loffler, J

“…Culture-based preemptive therapy with ganciclovir was shown to reduce the incidence of cytomegalovirus (CMV) disease after bone marrow transplantation (BMT)…”
Get full text

Antimicrobial Stewardship with and without Infectious Diseases Specialist Services to Improve Quality-of-Care in Secondary and Tertiary Care Hospitals in Germany: Study Protocol of the ID ROLL OUT Study by Zimmermann, Nicole, Allen, Rebekka, Fink, Geertje, Först, Gesche, Kern, Winfried V., Farin-Glattacker, Erik, Rieg, Siegbert

“…Background Antimicrobial stewardship (AMS) programs aim to secure the rational prescription of antibiotics through implementing department- or hospital-level…”
Get full text

Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection by EINSELE, H, HEBART, H, MÜLLER, C. A, KANZ, L, KAUFFMANN-SCHNEIDER, C, SINZGER, C, JAHN, G, BADER, P, KLINGEBIEL, T, DIETZ, K, LÖFFLER, J, BOKEMEYER, C

“…PCR-based preemptive therapy with ganciclovir has been shown to reduce the incidence of CMV disease after BMT. Failures of this treatment strategy are CMV…”
Get full text

Modification of human cytomegalovirus tropism through propagation in vitro is associated with changes in the viral genome by Sinzger, C, Schmidt, K, Knapp, J, Kahl, M, Beck, R, Waldman, J, Hebart, H, Einsele, H, Jahn, G

“…Department of Medical Virology 1 and Department of Medicine 3 , University of Tü bingen, Calwerstraße 7/6, D-72076 Tübingen, Germany Department of Pathology,…”
Get full text

Detection and identification of fungal pathogens in blood by using molecular probes by EINSELE, H, HEBART, H, SCHUMACHER, U, ROLLER, G, LÖFFLER, J, ROTHENHÖFER, I, MÜLLER, C. A, BOWDEN, R. A, VAN BURIK, J.-A, ENGELHARD, D, KANZ, L

“…Article Usage Stats Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text